Covington-Led Bristol Myers To Buy Karuna In $14B Deal
Covington & Burling LLP-advised Bristol Myers Squibb said Friday it has agreed to buy Boston-based biotechnology company Karuna Therapeutics Inc. for $14 billion, leading Karuna's stock to jump more than 47%...To view the full article, register now.
Already a subscriber? Click here to view full article